Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK’s Post-Advair Day Has Dawned, But Breo And Anoro Not Yet Shining

This article was originally published in The Pink Sheet Daily

Executive Summary

Decline in Advair sales to cointinue for several years as the portfolio transitions to new products, which have faced reimbursement challenges.

Advertisement

Related Content

China Scandal One Early Challenge For New GSK Chairman
Emerging Markets Earnings Roundup: GlaxoSmithKline (Part 4)
Emerging Markets Earnings Roundup: GlaxoSmithKline (Part 4)
GSK’s Breo Ellipta Marches Forward For Asthma, Efficacy Undistinguished From Advair
With Anoro, GSK Takes A Two-Step Toward Bolstering Respiratory
COPD Market Snapshot: New Products, Limited Differentiation

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS077478

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel